Cipla has received approval from board of directors to transfer Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences (CPLS), a wholly owned subsidiary of the Company. Effective date for completion of transfer to CPLS would be end of business hours of December 31, 2023, or such other date mutually agreed between the parties. The consideration to be received from such sale will be Rs 350 crore. The Board of Directors of the company at its meeting held on November 06, 2023 have inter alia, approved the same.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
